Orexo announces changes in the company´s Board of Directors
UPPSALA, Sweden, Oct. 27, 2023 /PRNewswire/ — Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors. Robin Evers replaces Henrik Kjaer Hansen, who has announced he will resign after having represented Orexo´s largest shareholder, Novo Holdings A/S, since 2018. Henrik Kjaer Hansen will continue to work closely with Orexo as chairman of Orexo´s.
Related news for (ORXOY)
- Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
- Orexo AB´s sustainability work ranked among top 5% by EcoVadis
- Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds